Oncology

The vaccine targets a protein that is no longer found after lactation in normal aging tissues but is present in most triple-negative breast cancers.

Because of the complexities of cardio-oncology medication regimens, pharmacists are vital to assess drug-drug interactions using multiple resources, such as databases, case reports, FDA and National Institutes of Health guidelines, and package inserts.

Indication for abemaciclib (Verzenio; Eli Lilly and Company) in combination with endocrine therapy expanded for the adjuvant treatment of adults with hormone receptor–positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer with a high risk of recurrence.

Although pharmacokinetics and dynamics can be complex, particularly in patients with cancer, pharmacists play a key role in the various considerations and treatment decisions.

Atrial fibrillation and atherosclerotic cardiovascular disease are frequent challenges among patients with cancer.

In part 1 of this panel discussion, experts address how they define traditional versus nontraditional oncology pharmacy roles today, as well as the benefits and drawbacks of pursuing such a career path based on their experience.

At 36 months, the overall survival rate of patients with relapsed/refractory B-cell acute lymphoblastic leukemia administered brexucabtagene autoleucel was 47.1%, with a median overall survival of 26 months.

The approach was based on previous research suggesting that foods rich in carotenoids, lycopene, certain B vitamins, and omega 3 fatty acids improved fatigue in survivors of breast cancer.

The inaugural Oncology Pharmacists Connect is directed toward pharmacists practicing in oncology in multiple practice environments.

Pembrolizumab showed statistically significant improvement in the event-free survival of patients with resectable stage 2 or 3 non-small cell lung cancer.

Therapy consists of high-dose abatacept, ruxolitinib, and proactive monitoring for respiratory muscle involvement.

The set of principles seeks to improve publication patterns to show the value of the pharmacist and how journals can strengthen pharmacy practice as a scientific discipline.

Metformin may accelerate paclitaxel’s actions on cell replication in endometrial cancer.

Data show continued objective response rate, overall survival, and progression-free survival benefits of nivolumab plus cabozantinib in the treatment of advanced renal cell carcinoma.

Two members of a clinical-stage authoring group discuss education programs and the alternative career path of medical writing, which can offer hybrid/virtual work-life balance opportunities.

Evaluating tasks, such as appropriate site of care and plan benefits, frees up time for pharmacists.

High-risk areas for disease progression include genitalia and the scalp.

Elranatamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody that may become the next standard of care for multiple myeloma, according to researchers.

An expert shares information on risk factors and controversies around testing.

Pharmacologic approaches can reduce the risk of chronic GVHD.

Positive data on the novel prostate cancer combination treatment was presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Olaparib with abiraterone increased survival in patients with metastatic prostate cancer compared to the current standard of care, according to a session at the ASCO Genitourinary Cancers Symposium.

The FDA approved darolutamide in 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer based improved metastasis-free survival.

Oncology pharmacists are as diverse as the cancers they manage and have key roles in the following areas of the cancer care continuum.

Each therapy presents a different but effective treatment option.

Pharmacists can be involved in all aspects of care, from deciding treatment plans to educating patients, and in the growing role of oral treatments.

Incidence of regional tumor recurrence in patients with HR–positive breast cancer did not significantly differ between patients who received post operational radiotherapy.

Novel drug development has been focused on the augmentation of the T-lymphocyte response.